1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

US FDA Principal Deputy Commissioner Bumpus Leaving At Year’s End, Creating Leadership Void

 
• By Sue Sutter

Namandje Bumpus' departure means there is no obvious, internal candidate to serve as acting commissioner when President-elect Donald Trump takes office in January and the Senate works to confirm a new leader.

Goodbye with clock
Namandje Bumpus is saying goodbye to the US FDA. (Shutterstock)
Key Takeaways
  • Principal Deputy Commissioner Namandjé Bumpus’ decision to resign at the end of the year eliminates her as the obvious internal candidate for acting commissioner until the Trump Administration’s expected nominee, Martin Makary, is confirmed.
  • The new administration could appoint someone who is already a federal employee as acting commissioner, but not until Donald Trump takes office on 20 January 2025.
  • Commissioner Robert Califf lauded Bumpus for her work planning and overseeing the largest reorganization in the agency’s history.

US Food and Drug Administration Principal Deputy Commissioner Namandjé Bumpus’ decision to leave by the end of the year means there is no obvious, internal candidate to serve as acting...

Commissioner Robert Califf also is expected to depart the agency when President-elect Donald Trump is inaugurated on 20 January.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

US FDA Punts On New COVID-19 Framework’s Impact On Fall Shots

 
• By Sarah Karlin-Smith

The FDA’s advisors split on whether to update COVID-19 vaccines for the fall. The agency refused to discuss the impact of the new vaccine framework on availability.

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

Legal, Process Problems May Plague New US FDA COVID-19 Vaccine Policy

 
• By Sarah Karlin-Smith

The FDA may have violated laws and regulations along with many norms in how it released its planned changes for COVID-19 vaccine approvals.

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.

More from Geography

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.